Drug Profile
Research programme: transdermal therapeutics - Aequus Pharmaceuticals
Alternative Names: AQS 1302; AQS 1304; Cannabinoid transdermal delivery system; Clobazam transdermal patchLatest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Aequus Pharmaceuticals
- Class Antidementias; Antiemetics; Antiepileptic drugs; Anxiolytics; Benzodiazepines; Cannabinoids; Picolines; Pyridines; Sedating antihistamines; Small molecules; Vitamins
- Mechanism of Action Biogenic monoamine uptake modulators; Cannabinoid receptor modulators; GABA A receptor agonists; Histamine H1 receptor antagonists; Neurotransmitter stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease; Epilepsy; Nausea
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Alzheimer's-disease in Canada (Transdermal)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Epilepsy in Canada (Transdermal, Patch)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Nausea in Canada (Transdermal, Patch)